Get the Stockscreener App
1.183
7.14%
0.063
Rein Therapeutics Inc stock is traded at $1.183, with a volume of 42,225.
It is up +7.14% in the last 24 hours and down -20.53% over the past month.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
See More
Previous Close:
$1.12
Open:
$1.12
24h Volume:
42,225
Relative Volume:
0.98
Market Cap:
$26.16M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.00%
1M Performance:
-20.53%
6M Performance:
-47.83%
1Y Performance:
+0.00%
1-Day Range:
$1.12
$1.24
1-Week Range:
$1.04
$1.39
52-Week Range:
$1.04
$3.50
Rein Therapeutics Inc Stock (RNTX) Company Profile
Name
Rein Therapeutics Inc
Sector
Industry
Phone
(737) 802-1989
Address
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.181 | 24.59M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
378.67 | 118.67B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.59 | 59.23B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.81 | 52.67B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
679.18 | 41.24B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
309.10 | 32.36B | 3.81B | -644.79M | -669.77M | -6.24 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-24-17 | Initiated | BofA/Merrill | Buy |
| Jul-24-17 | Initiated | Jefferies | Buy |
| Jul-24-17 | Initiated | William Blair | Outperform |
Rein Therapeutics Inc Stock (RNTX) Latest News
Signal strength of Rein Therapeutics Inc. stock in tech scannersAsset Allocation Summary With Future Outlook - Newser
Custom Dashboard Highlights Rein Therapeutics Inc. Price MomentumFree Stock Market Beginners Guide - beatles.ru
Market reaction to Rein Therapeutics Inc.’s recent newsReal-Time Investment Picks with Accuracy - Newser
Published on: 2025-08-04 15:51:03 - beatles.ru
Bollinger Bands Expand on Rein Therapeutics Inc. — Volatility AheadNews Based Entry Opportunity Alerts Detected - metal.it
Using Bollinger Bands to evaluate Rein Therapeutics Inc.Free Weekly Growth Stock Entry Point Alerts - Newser
What institutional investors are buying Rein Therapeutics Inc. stockInvest confidently with professional advice - Jammu Links News
Published on: 2025-08-04 07:26:22 - metal.it
What makes Rein Therapeutics Inc. stock price move sharplyFast Movement Forecast for Trading Success - Newser
Why Rein Therapeutics Inc. stock attracts strong analyst attentionHigh Win Rate Strategy with Stop Protection - Newser
What are the technical indicators suggesting about Rein Therapeutics Inc.Discover high-impact stocks for growth - Jammu Links News
Top Risks to Consider Before Buying Rein Therapeutics Inc. StockSector Rotation Strategy for Smart Traders - Newser
Rein Therapeutics Inc. Stock Analysis and ForecastMaximize your portfolio’s earning power - Jammu Links News
What machine learning models say about Rein Therapeutics Inc.Portfolio Risk Distribution Analysis Tool - Newser
How strong is Rein Therapeutics Inc. company’s balance sheetRobust investment performance - Jammu Links News
How Rein Therapeutics Inc. stock performs during market volatilityLong-Term Investment Strategy Summary Guide - Newser
Published on: 2025-08-03 12:00:42 - Jammu Links News
What is the risk reward ratio of investing in Rein Therapeutics Inc. stockUnlock daily market insights for better trades - Jammu Links News
How volatile is Rein Therapeutics Inc. stock compared to the marketCapitalize on proven investment strategies - Jammu Links News
Should I hold or sell Rein Therapeutics Inc. stock in 2025Rapidly growing investment returns - Jammu Links News
What are Rein Therapeutics Inc. company’s key revenue driversExceptional stock performance - Jammu Links News
Is Rein Therapeutics Inc. a good long term investmentMarket-leading profit generation - Jammu Links News
Chart based exit strategy for Rein Therapeutics Inc.Free Fast Return Equity Trade Forecast - Newser
Is Rein Therapeutics Inc. stock poised for growthFree Triple Digit Return Stock Predictions - Newser
How sentiment analysis helps forecast Rein Therapeutics Inc.Weekly Trend Watch with Market Signals - Newser
Regression analysis insights on Rein Therapeutics Inc. performanceFree Oversold Bounce Stock Play Ideas - Newser
Rein Therapeutics Completes Promising IPF Treatment Study - TipRanks
Intraday pattern recognizer results for Rein Therapeutics Inc.Free Fast Exit and Entry Strategy Guide - Newser
Rein Therapeutics Secures New Financial Agreements - TipRanks
Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing - GlobeNewswire
Rein Therapeutics secures up to $21 million in strategic financing By Investing.com - Investing.com Canada
Rein Therapeutics' $21M Financing: Balancing Strategic Flexibility and Shareholder Dilution in a High-Stakes IPF Trial - AInvest
Rein Therapeutics Inc. Shows Early Signs of Technical StrengthStrong Buy With Technical Confidence Supported - metal.it
Published on: 2025-07-29 14:28:02 - metal.it
Price action breakdown for Saia Inc.Predicted Market Direction Based on Momentum - Newser
Real time pattern detection on GUTS stockROI Focused Setup With Drawdown Analysis - Newser
Rein Therapeutics Inc Stock (RNTX) Financials Data
There is no financial data for Rein Therapeutics Inc (RNTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.71%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):